NewAmsterdam Pharma Company N.V. (NAMSW)
NGM
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Peers in industry
NewAmsterdam Pharma Company N.V. has no peer companies in this window.
Recent press releases
April 2026
NAMSW proxies request shareholder approval for 2025 accounts and structure
# 📜 What This Document Is 📄 This document is a Preliminary Proxy Statement (PRE 14A). Think of it as the comprehensive instruction manual for the company's upcoming annual shareholder meeting. It's *not* an earnings report; instead, it outlines what the company is asking you, the shareholder, to v
SEC filings
All filings →Insider trades
All insider trades →NewAmsterdam Pharma Company N.V. has no reported insider trades in the last 90 days.
Institutional holders
All holders →People at NewAmsterdam Pharma Company N.V.
All people →No officers or directors have been indexed for NewAmsterdam Pharma Company N.V..